ALK and non-small cell lung carcinoma: Recently, Xu et al. (2019) tried to build a radiomic signature to predict pretreatment BM for stage III/IV ALK-positive NSCLC patients and found that only one radiomic feature (W_GLCM_LH_Correlation) was an independent predictor (training set: AUC = 0.687, test set: AUC = 0.642), which also exhibited reposeful performance in predicting BM during follow-up (stage III: AUC = 0.682, stage IV: AUC = 0.653).